Redhill Biopharma Price To Earning vs. Revenue

RDHL Stock  USD 7.91  0.11  1.41%   
Based on the key profitability measurements obtained from Redhill Biopharma's financial statements, Redhill Biopharma is performing exceptionally good at this time. It has a great probability to showcase excellent profitability results in December. Profitability indicators assess Redhill Biopharma's ability to earn profits and add value for shareholders. The value of Price To Sales Ratio is estimated to slide to 34.49. The value of Days Sales Outstanding is estimated to slide to 174.89. At this time, Redhill Biopharma's Interest Income is quite stable compared to the past year. Change To Netincome is expected to rise to about 29.7 M this year, although the value of Income Tax Expense is projected to rise to (1.90).
For Redhill Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Redhill Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Redhill Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Redhill Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Redhill Biopharma over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center.
For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(302.63)
Revenue Per Share
4.733
Quarterly Revenue Growth
(0.28)
Return On Assets
(0.45)
Return On Equity
(17.09)
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Redhill Biopharma Revenue vs. Price To Earning Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Redhill Biopharma's current stock value. Our valuation model uses many indicators to compare Redhill Biopharma value to that of its competitors to determine the firm's financial worth.
Redhill Biopharma is rated below average in price to earning category among its peers. It is rated below average in revenue category among its peers . At this time, Redhill Biopharma's Total Revenue is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Redhill Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Redhill Revenue vs. Price To Earning

Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

Redhill Biopharma

P/E

 = 

Market Value Per Share

Earnings Per Share

 = 
(3.67) X
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Redhill Biopharma

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
6.51 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Redhill Revenue vs Competition

Redhill Biopharma is rated below average in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 2.07 Billion. Redhill Biopharma adds roughly 6.51 Million in revenue claiming only tiny portion of equities under Health Care industry.

Redhill Biopharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Redhill Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Redhill Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Redhill Biopharma's change in net profit over the period of time. It can combine multiple indicators of Redhill Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-399.6 K-379.6 K
Operating Income12.6 M13.3 M
Income Before Tax24 M25.1 M
Total Other Income Expense Net11.3 M11.9 M
Net Income23.9 M25.1 M
Income Tax Expense(2.00)(1.90)
Net Income From Continuing Ops23.9 M25.1 M
Net Loss-88 M-83.6 M
Net Interest Income-2.2 M-2.3 M
Interest Income94 K176.2 K
Change To Netincome28.3 M29.7 M
Net Income Per Share 3.69  3.88 
Income Quality(1.50)(1.42)
Net Income Per E B T 1.00  1.14 

Redhill Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Redhill Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Redhill Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Redhill Biopharma's important profitability drivers and their relationship over time.

Use Redhill Biopharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Redhill Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Redhill Biopharma will appreciate offsetting losses from the drop in the long position's value.

Redhill Biopharma Pair Trading

Redhill Biopharma Pair Trading Analysis

The ability to find closely correlated positions to Redhill Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Redhill Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Redhill Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Redhill Biopharma to buy it.
The correlation of Redhill Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Redhill Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Redhill Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Redhill Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Redhill Biopharma position

In addition to having Redhill Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Social Domain Thematic Idea Now

Social Domain
Social Domain Theme
New or established large and mid-sized companies that are involved in the social media industry, including entities that provide web-based or mobile media applications and services across across large segment of population in multiple geographical areas. The Social Domain theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Social Domain Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Redhill Biopharma is a strong investment it is important to analyze Redhill Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Redhill Biopharma's future performance. For an informed investment choice regarding Redhill Stock, refer to the following important reports:
Check out Your Equity Center.
For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.
You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
To fully project Redhill Biopharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Redhill Biopharma at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Redhill Biopharma's income statement, its balance sheet, and the statement of cash flows.
Potential Redhill Biopharma investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Redhill Biopharma investors may work on each financial statement separately, they are all related. The changes in Redhill Biopharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Redhill Biopharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.